结直肠癌k-ras基因检测及其靶向治疗的研究现状  

Recent advances in detection of k-ras gene mutations and targeted therapy of colorectal cancer

作　　者：王丽[1] 余英豪[1] 

机构地区：[1]中国人民解放军南京军区福州总医院病理科,福建省福州市350025

出　　处：《世界华人消化杂志》2011年第1期62-67,共6页World Chinese Journal of Digestology

摘　　要：越来越多的研究表明,EGFR单抗对k-ras基因野生型结直肠癌患者治疗有效.k-ras基因编码的K-ras蛋白为EGFR信号通路下游区的一种小分子G蛋白,k-ras基因发生突变后,导致该信号通路异常活化,从而对EGFR单抗治疗无效.因此,检测k-ras基因状态对指导结直肠癌患者靶向治疗十分重要.本文就k-ras基因检测方法及与结直肠癌靶向治疗的研究现状进行综述.Numerous studies have shown that anti-epidermal growth factor receptor （EGFR） monoclonal antibodies are effective in the treatment of colorectal cancer patients with the wild-type k-ras gene. The k-ras gene encodes a G-protein that functions downstream of EGFR signaling. Since k-ras mutations result in abnormal activation of the EGFR signaling pathway, anti-EGFR monoclonal antibody treatment is ineffective for patients with k-ras mutations. Therefore, k-ras mutation analysis is very important for targeted therapy of patients with colorectal cancer. This paper gives an overview of the recent advances in detection of k-ras gene mutations and targeted therapy of colorectal cancer.

关 键 词：结直肠癌 K-RAS基因 突变 靶向治疗 检测方法 

分 类 号：R735.3[医药卫生—肿瘤]